International transporter consortium commentary on clinically important transporter polymorphisms

K. M. Giacomini, P. V. Balimane, S. K. Cho, M. Eadon, T. Edeki, K. M. Hillgren, S. M. Huang, Y. Sugiyama, D. Weitz, Y. Wen, C. Q. Xia, S. W. Yee, H. Zimdahl, M. Niemi

Research output: Contribution to journalReview article

96 Scopus citations


This Commentary focuses on genetic polymorphisms in membrane transporters. We present two polymorphisms for which there is a compelling body of literature supporting their clinical relevance: OATP1B1 (c.521T>C, p.V174A, rs4149056) and BCRP (c.421C>A, p.Q141K, rs2231142). The clinical evidence demonstrating their role in variation in pharmacokinetics and pharmacodynamics is described along with their allele frequencies in ethnic populations. Recommendations for incorporating studies of transporter polymorphisms in drug development are provided, along with the regulatory implications.

Original languageEnglish (US)
Pages (from-to)23-26
Number of pages4
JournalClinical Pharmacology and Therapeutics
Issue number1
StatePublished - Jul 1 2013


ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Giacomini, K. M., Balimane, P. V., Cho, S. K., Eadon, M., Edeki, T., Hillgren, K. M., Huang, S. M., Sugiyama, Y., Weitz, D., Wen, Y., Xia, C. Q., Yee, S. W., Zimdahl, H., & Niemi, M. (2013). International transporter consortium commentary on clinically important transporter polymorphisms. Clinical Pharmacology and Therapeutics, 94(1), 23-26.